Why Pancreatic Cancer Drug Daraxonrasib Eventually Stops Working
Researchers investigate why patients inevitably develop resistance to the breakthrough pancreatic cancer drug daraxonrasib.
This story has stopped developing; this page is its permanent record. More from that day
The story so far
1 publisher has covered this in 1 article since 30 Sept 2026. The New York Times published first, on 30 September at 17:48 UTC.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Ben Sasse